UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as it fights to retain its stock market listing in the US.
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data drop for Alzheimer's therapy lecanemab – but a number of breakwaters could lie ahead.
Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di
Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.
GSK has said that its chief financial officer Iain Mackay will stand down from the role in May next year, to be replaced by Julie Brown, currently chief operating and financial officer at l
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.